摘要
心血管疾病与脂质紊乱有着极其紧密的联系,在治疗过程中降低低密度脂蛋白胆固醇(LDL-C)的水平,可以显著降低冠状动脉疾病(CAD)和急性心血管事件的发病率和致死率。他汀类药物有着良好的降LDL—C效果。最近研究还发现,他汀类药物还具有改善血管内皮功能和抗炎的特性,这些都提示他汀类药物可能对动脉粥样硬化也有治疗作用,同时其改善血管功能和凋节炎性反应的作用已经成为了研究的热点。但是,随着他汀类药物的广泛应用,
出处
《中国药房》
CAS
CSCD
北大核心
2010年第24期2298-2300,共3页
China Pharmacy
参考文献20
-
1Hajer GR, Dallinga-Thie GM, van Vark-van der Zee LC, et al. The effect of statin alone or in combination with ezetimibe on postprandial lipoprotein composition in obese metabolic syndrome patients [J]. Atherosclerosis, 2009, 202(1): 216.
-
2Olijhoek JK, Hajer GR, van der Graaf Y, et al, The effects of low-dose simvastatin and ezetimibe compared to high-dose simvastatin alone on post-fat load endothelial function in patients with metabolic syndrome: a randomized double-blind crossover trial [J]. J Cardiovasc Pharmacol, 2008, 52(2): 145.
-
3Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia [J]. J Am Coll Cardiol, 2002,40 (12) : 2 125.
-
4Maki-Petaja KM, Booth AD, Hall FC, et al. Ezetimibe and simvastatin reduce inflammation, disease activity, and aortic stiffness and improve endothelial function in rheumatoid arthritis [J]. J Am Coil Cardiol, 2007, 50 (9) : 852.
-
5Kastelein JJ, Akdim F, Stroes ES, et al. Simvastatin with or without ezetimibe in familial hypercholesterolemia [J]. NEnglJMed, 2008, 358(14): 1 431.
-
6Peto R, Emberson J, Landray M, et al. Analyses of cancer data from three ezetimibe trials [J]. N Engl J Med, 2008, 359(13) : 1 357.
-
7Pedersen TR, Tobert JA. Simvastatin: a review [J]. Expert Opin Pharmacother, 2004, 5(12) : 2 583.
-
8Capps N. Total and low-density lipoprotein cholesterol responses to ezetimibe in clinical practice [J]. Int J Clin Pract, 2006, 60(7): 867.
-
9Pearson TA, Denke MA, McBride PE, et al. A community-based, randomized trial of ezetimibe added to statin therapy to attain NCEP ATP IlI goals for LDL cholesterol in hypercholesterolemic patients: the ezetimibe add-on to statin for effectiveness (EASE) trial [J]. Mayo Clin Proc, 2005, 80(5): 587.
-
10Ballantyne CM, Abate N, Yuan Z, et al. Dose-comparison study of the combination of ezetimibe and simvastatin (Vytorin) versus atorvastatin in patients with hypercholesterolemia: the Vytorin Versus Atorvastatin (VYVA) study [ J]. Am Heart J, 2005, 149(3): 464.
同被引文献26
-
1中国成人血脂异常防治指南[J].中华心血管病杂志,2007,35(5):390-419. 被引量:5230
-
2何甲均,徐学广,郑莘.辛伐他汀和盐酸小檗碱治疗高脂血症和颈动脉粥样硬化的疗效[J].天津医药,2007,35(7):539-541. 被引量:3
-
3中华人民共和国卫生部药政管理局.新药(西药)临床研究指导原则[M].北京:人民卫生出版社,1993:51.
-
4Filippatos TD, Randeva HS, Derdemezis CS, el al. Visfatin/ PBEF and atherosclerosis related diseases J 1. Curr Vase Pharmacol, 2010, 8(1) :12 28.
-
5Dahl TB, Yndcstad A, Skjelland M, el al. Increased expres sion of visfatin in macrophages of hun,an unstable carotid and coronary atherosclerosis: possible role in inflammation and plaque destabilization [J. Circulation, 2007, 115 (8) : 972- 980.
-
6Hah YJ, Kim NK, Kim MK, el al. Relationship hetween Chemerin Lords and Cardiometabolic Parameters and Degree of Coronary Stenosis in Korean Patients with Coronary Artery Disease[J]. Diabetes Metab ,1, 2011, 35 (3) = 248 254.
-
7Gensini GG. A more meaningful scoring system for determi ning the severity of coronary heart discasc[J]. Am J Cardiol, 1983, 51(3):606.
-
8Stofkova A. Resistin and visfatin: regulators of insulin sensi tivity, inflammation and immunity[J]. Endocr Regul, 2010, 44(1):25 36.
-
9Filippatos TD, Randew HS, Derdemezis CS, el al. Visfatin/ PBEF and atherosclerosis related diseases -J . Curr Vase Pharmacol, 20 10, 8 ( 1 ) : 12 28.
-
10Kadoglou NP, Gkontopoulos A, Kapelouzou A, el al. Serum levels of vaspin and visfatin in patients with coronary artery diseaseKozanistudyJ. ClinChimActa, 2011,412(1 2):48 52.
二级引证文献27
-
1贾维敏,张志.依折麦布联合辛伐他汀治疗2型糖尿病合并高脂血症的临床观察[J].中国医学创新,2014,11(25):65-67. 被引量:5
-
2户波,靳红勋.不同剂量辛伐他汀治疗老年高脂血症效果对比分析[J].中国实用医药,2015,10(3):14-16. 被引量:5
-
3庄再生.对比不同剂量的辛伐他汀治疗社区高脂血症的临床应用效果[J].中国现代药物应用,2015,9(11):9-11. 被引量:4
-
4曾远强,张燕辉.银杏叶胶囊与阿伐他汀胶囊治疗高脂血症疗效观察[J].齐齐哈尔医学院学报,2015,36(12):1767-1769. 被引量:3
-
5王进雄,谭林.辛伐他汀剂量对老年高脂血症患者疗效与安全性的影响[J].中国现代药物应用,2015,9(12):21-22. 被引量:3
-
6崔卫华,丁军,黄通瑞.不同剂量辛伐他汀治疗老年高脂血症临床疗效探讨[J].中国医院用药评价与分析,2015,15(5):662-663. 被引量:9
-
7陈俊媛.高脂血症应用辛伐他汀不同剂量治疗的疗效分析[J].中国实用医药,2015,10(31):171-172.
-
8张坤.辛伐他汀治疗高脂血症的疗效评估及报道分析[J].中国医药指南,2016,14(8):37-38.
-
9韦之富,郭姣,荣向路,朴胜华.高剂量辛伐他汀治疗48例老年高脂血症的临床效果[J].实用临床医药杂志,2016,20(7):158-159. 被引量:7
-
10杨迎东.瑞舒伐他汀与阿托伐他汀对老年高脂血症有效性、安全性及经济性对比[J].中国现代药物应用,2016,10(11):160-161. 被引量:1
-
1袁祖贻,胡大一.新型口服抗凝药物在心血管领域的研究进展[J].中华心血管病杂志,2013,41(11):988-991. 被引量:6
-
2杜有仪.他汀类药物治疗心血管疾病研究进展[J].中国心血管杂志,2001,6(3):178-180. 被引量:14
-
3孔祥姣,陶贵周.氯吡格雷抵抗研究进展[J].临床误诊误治,2009,22(5):78-79. 被引量:6
-
4郝欣.浅谈心律失常常用药物分析[J].中国现代药物应用,2015,9(4):231-232. 被引量:1
-
5USC研究人员称不应忽视雌激素的有利效应[J].中华医学信息导报,2006,21(6):9-9.
-
6高铁山.降脂治疗,非“他汀类”莫属吗?[J].糖尿病天地,2006(9):34-34.
-
7JonesPH,兰永乔,曾朝荣.他汀类药物是治疗脂质紊乱的基石:单用或联合应用的选择[J].心血管病学进展,2005,26(2):214-215.
-
8柏志强,曾淑云.低分子肝素治疗不稳定型心绞痛的效果观察[J].现代医院,2005,5(7):57-58.
-
9李莉.慢性稳定性心绞痛诊治指南应用与社区管理[J].中国临床医生杂志,2009,37(2):69-72. 被引量:2
-
10陈刘颜.国产替罗非班治疗急性冠脉综合征患者的疗效观察与护理干预[J].中华现代护理杂志,2008,14(25):2687-2689. 被引量:1